Physician profile
Juan Joy
NPI 1992759807
$1,815.86
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $261 · 2021: $151 · 2022: $810 · 2023: $182 · 2024: $25.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $206.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $279.75 | 2021-2023 | |
| Celgene Corporation | $265.48 | 2022 | |
| Novartis Pharmaceuticals Corporation | $128.49 | 2019-2023 | |
| Amgen INC. | $119.19 | 2019 | |
| Glaxosmithkline, LLC. | $100.17 | 2022 | |
| Argenx US, INC. | $86.35 | 2022-2023 | Vyvgart |
| Pfizer INC. | $82.70 | 2019 | |
| Allergan, INC. | $77.94 | 2019-2020 | |
| Biogen, INC. | $75.68 | 2019-2021 | |
| Emd Serono, INC. | $68.50 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $63.56 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $48.69 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $42.38 | 2020-2021 | |
| Genzyme Corporation | $36.79 | 2019-2022 | |
| Ucb, INC. | $33.53 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $32.98 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.96 | 2022 | |
| Boston Scientific Corporation | $25.26 | 2024 | Wavewriter Alpha Prime 16 |
| Sk Life Science, INC. | $24.73 | 2022 | |
| Silk Road Medical, INC. | $23.03 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Avanir Pharmaceuticals, INC. | $21.22 | 2021 | |
| Horizon Therapeutics Plc | $19.85 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.64 | 2023 | Nuedexta |
| Zimmer Biomet Holdings, INC. | $18.53 | 2020 | |
| Acorda Therapeutics, INC | $15.75 | 2020 | |
| Greenwich Biosciences, INC. | $15.59 | 2019 | |
| Banner Life Sciences, LLC | $15.49 | 2021 | |
| Lilly USA, LLC | $15.39 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.67 | 2020 | |
| Acadia Pharmaceuticals INC | $14.57 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Joy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.